122 related articles for article (PubMed ID: 8033956)
1. Increase in plasma 3,4-dihydroxyphenylalanine (DOPA) appearance rate after inhibition of DOPA decarboxylase in humans.
Eldrup E; Hetland ML; Christensen NJ
Eur J Clin Invest; 1994 Mar; 24(3):205-11. PubMed ID: 8033956
[TBL] [Abstract][Full Text] [Related]
2. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid.
Eldrup E; Møller SE; Andreasen J; Christensen NJ
Clin Sci (Lond); 1997 Apr; 92(4):423-30. PubMed ID: 9176043
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
4. Sympathoadrenal contribution to plasma dopa (3,4-dihydroxyphenylalanine) in rats.
Grossman E; Hoffman A; Armando I; Abassi Z; Kopin IJ; Goldstein DS
Clin Sci (Lond); 1992 Jul; 83(1):65-74. PubMed ID: 1325324
[TBL] [Abstract][Full Text] [Related]
5. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
7. Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity of the rat locus ceruleus.
Robert F; Lambás-Señas L; Ortemann C; Pujol JF; Renaud B
J Neurochem; 1993 Feb; 60(2):721-9. PubMed ID: 8093483
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of dopamine from L-3,4-dihydroxyphenylalanine by human amniotic epithelial cells.
Elwan MA
Eur J Pharmacol; 1998 Jul; 354(1):R1-2. PubMed ID: 9726639
[TBL] [Abstract][Full Text] [Related]
9. Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2.
Vieira-Coelho MA; Soares-Da-Silva P
Am J Physiol; 1998 Jul; 275(1):C104-12. PubMed ID: 9688840
[TBL] [Abstract][Full Text] [Related]
10. A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine.
Brown MJ; Dollery CT
Br J Clin Pharmacol; 1981 Jan; 11(1):79-83. PubMed ID: 6783056
[TBL] [Abstract][Full Text] [Related]
11. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.
Kent AP; Stern GM; Webster RA
Br J Pharmacol; 1990 Aug; 100(4):743-8. PubMed ID: 2119841
[TBL] [Abstract][Full Text] [Related]
12. Defective 3,4-dihydroxyphenylalanine decarboxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable.
Shigetomi S; Kuchel O
Am J Hypertens; 1993 Jan; 6(1):33-40. PubMed ID: 8427659
[TBL] [Abstract][Full Text] [Related]
13. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
Bakke OM; Scheline RR
J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
[No Abstract] [Full Text] [Related]
16. Increased plasma dihydroxyphenylalanine during sympathetic activation in humans is related to increased norepinephrine turnover.
Eisenhofer G; Meredith IT; Ferrier C; Cox HS; Lambert G; Jennings GL; Esler MD
J Lab Clin Med; 1991 Apr; 117(4):266-73. PubMed ID: 1901341
[TBL] [Abstract][Full Text] [Related]
17. Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans.
Wolfovitz E; Grossman E; Folio CJ; Keiser HR; Kopin IJ; Goldstein DS
Clin Sci (Lond); 1993 May; 84(5):549-57. PubMed ID: 8504632
[TBL] [Abstract][Full Text] [Related]
18. Hypothalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxylase activity.
Reymond MJ; Porter JC
Endocrinology; 1982 Oct; 111(4):1051-6. PubMed ID: 6811255
[TBL] [Abstract][Full Text] [Related]
19. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
20. Effects of a decarboxylase inhibitor on the Dopa and 5-HTP induced changes in the locomotor-like discharge pattern of rabbit hind limb nerves.
Viala D; Buser P
Psychopharmacologia; 1974; 40(3):225-33. PubMed ID: 4548539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
